Revolution Medicines, Inc. Amortization of Debt Issuance Costs
Revolution Medicines, Inc. (RVMD) reported Amortization of Debt Issuance Costs of $656.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2026-08-05
- Revolution Medicines, Inc. amortization of debt issuance costs for the quarter ending 2026-06-30 was $419.00K.
- Revolution Medicines, Inc. amortization of debt issuance costs for the quarter ending 2026-03-31 was $237.00K.
- Revolution Medicines, Inc. amortization of debt issuance costs for the quarter ending 2025-12-31 was $255.00K.
- Revolution Medicines, Inc. amortization of debt issuance costs for the quarter ending 2025-09-30 was $266.00K.
- Revolution Medicines, Inc. amortization of debt issuance costs for fiscal 2025 was $541.00K.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $419.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $656.00K 10-Q · filed 2026-08-05 | $911.00K derived: sum of 3 quarters · filed 2026-08-05 | $1.18M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $237.00K 10-Q · filed 2026-05-06 | $492.00K derived: sum of 2 quarters · filed 2026-05-06 | $758.00K derived: sum of 3 quarters · filed 2026-05-06 | |
| 2025-12-31 | $255.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $521.00K derived: sum of 2 quarters · filed 2026-02-25 | $541.00K 10-K · filed 2026-02-25 | |
| 2025-09-30 | $266.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $286.00K 10-Q · filed 2025-11-05 | ||
| 2025-06-30 | $20.00K 10-Q · filed 2025-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |